30th Mar 2022 19:23
Proteome Sciences PLC - drug development services provider - Amends GBP1 million loan with Vulpes Investment Management Private Ltd, which was signed in the summer of 2018. Accrued interest now repayable on June 30, 2023, extended from May 1, 2022. Notes GBP700,000 is currently drawn on facility.
Martin Diggle, non-executive director of Proteome Sciences, is a director and partner of VIM. VIM manages the Vulpes Life Sciences Fund, which owns a 22.3% stake in Proteome Sciences.
Current stock price: 3.62 pence
12-month change: down 28%
By Paul McGowan; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Proteome